NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
NeuroSense Therapeutics Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$2.67−0.40 (-13.19%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
NeuroSense Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | NeuroSense Therapeutics | Industry median |
|---|---|---|
| Market Cap | $4.89M | $166.30M |
| Enterprise Value | $4.66M | $88.19M |
Income (trailing twelve months)
| Measure | NeuroSense Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$11.09M | -$21.40M |
| Net Income | -$11.13M | -$22.46M |
| EBITDA | -$11.09M | -$16.91M |
| EPS (Diluted) | -$8.80 | -$0.83 |
Returns
| Measure | NeuroSense Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -862.4% | -40.9% |
Balance sheet
| Measure | NeuroSense Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $231.00K | $61.43M |
| Net Cash (Debt) | $231.00K | $15.35M |
| Net Cash Per Share | $0.13 | $0.66 |
| Equity (Book Value) | -$2.10M | $49.09M |
| Book Value Per Share | -$1.15 | $1.37 |
| Tangible Book Value | -$2.10M | $23.52M |
| Working Capital | -$2.16M | $76.81M |
Financial position
| Measure | NeuroSense Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.28 | 3.34 |
| Quick Ratio | 0.08 | 2.44 |
Cash flow (trailing twelve months)
| Measure | NeuroSense Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$7.67M | -$12.35M |
| Capital Expenditures | -$8.00K | -$1.08M |
| Free Cash Flow | -$7.68M | -$20.22M |
| FCF Per Share | -$4.18 | -$0.42 |
Efficiency
| Measure | NeuroSense Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$556.25K | -$703.34K |
| Employee Count | 20 | 74 |
Dividends and yields
| Measure | NeuroSense Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -227.3% | -23.3% |
| FCF Yield | -156.9% | -8.72% |
| Buyback Yield | -0.14% | -0.59% |
| Shareholder Yield | -0.14% | 0.00% |
Shares
| Measure | NeuroSense Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 1,836,150 | 58,127,000 |
| Shares Change (YoY) | 37.0% | 10.9% |
Scores
| Measure | NeuroSense Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -122.97 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from NeuroSense Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.